Tag:

Diamyd Medical

Latest Headlines

Latest Headlines

Combo-happy Diamyd launches new diabetes vaccine trial in children

March 12, 2015 | By
Diabetes vaccine developer Diamyd Medical is running a Phase II test to see if its candidate, Diamyd, can prevent or delay the onset of Type 1 diabetes in children at very high risk of presenting with the disease.

Protein Sciences nabs stake in diabetes vax developer Diamyd

September 18, 2014 | By
With its candidate diabetes vaccine in Phase II combo studies, Diamyd Medical is seeing some new investment--including a bumped-up agreement with longtime partner Protein Sciences.

Diamyd Medical sells off nerve-targeted delivery unit

FierceDrugDelivery | October 9, 2012
Swedish company Diamyd Medical has sold off its U.S. subsidiary, Diamyd, and its nerve-delivery system, designed to deliver drugs to treat pain directly to the nervous system. The buyer is Periphagen Holdings, a company created and owned by the Diamyd management.

Modified herpes simplex virus delivers anti-pain gene therapy

FierceDrugDelivery | April 12, 2011
University of Michigan researchers are reporting success in easing pain in cancer sufferers using gene therapy delivered by a modified herpes simplex virus (HSV). David Fink, chair of the Department
Related Tags
Press Releases
  • FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa
  • Emisphere Signs License Agreement With Novo Nordisk to Develop Oral Formulations of Four Molecules Targeting Metabolic Indications and Amends GLP-1 Agreement
  • FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa
  • EARLY HUMAN CASES WITH EDWARDS FORMA TRICUSPID REPAIR SYSTEM PRESENTED AT TCT
  • EARLY HUMAN CASES WITH EDWARDS FORM A TRICUSPID REPAIR SYSTEM PRESENTED AT TCT
  • More Press Releases
Sponsored Links